Avricore Health Inc. reports profit growth and revenue increase in the first quarter of 2024.

From GlobeNewswire: 2024-06-03 08:00:00

Avricore Health Inc. (TSXV: AVCR) reported a net comprehensive income of $168,537 for the first quarter of 2024, showing profitability for the company. Revenue increased by 79% year over year to $1,124,307, with a gross margin of 43%. The company is focused on growth, managing efficiencies, and expanding HealthTab™ offerings in Canada and internationally.

The company is actively seeking expansion opportunities, such as integrating with Ascensia Diabetes Care for blood glucose monitoring systems and launching in Rexall Pharmacies. Avricore Health Inc. aims to collaborate with various parties to enhance patient health care both locally and globally. The company’s objectives include expanding HealthTab™ with current partners, hiring key positions, and achieving revenue growth and profitability.

HealthTab™ is a comprehensive point-of-care testing solution that provides lab-accurate results on the spot with just a few drops of blood. With up to 23 key biomarkers available, including tests for chronic diseases like diabetes and heart disease, HealthTab™ empowers pharmacists to play a greater role in primary care delivery. The system also offers testing capabilities for bacterial and viral infections, such as strep and COVID-19.



Read more at GlobeNewswire:: AVRICORE HEALTH CORPORATE UPDATE – COMPANY ACHIEVES